In the course of breast cancer global gene expression studies, we identified an uncharacterized gene known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients with recurrent disease. In this study, we identified RHBDD2 mRNA and protein expression significantly elevated in breast carcinomas compared with normal breast samples as analyzed by SAGE (n =46) and immunohistochemistry (n = 213). Interestingly, specimens displaying RHBDD2 over-expression were predominantly advanced stage III breast carcinomas (p = 0.001). Western-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer cell lines. We further investigated the occurrence and frequency of gene amplification and over-expression affecting RHBDD2 in 131 breast samples. RHBDD2 gene amplification was detected in 21% of 98 invasive breast carcinomas analyzed. However, no RHBDD2 amplification was detected in normal breast tissues (n = 17) or breast benign lesions (n = 16) (p = 0.014). Interestingly, siRNA-mediated silencing of RHBDD2 expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding controls (p = 0.001). In addition, analysis of publicly available gene expression data showed a strong association between high RHBDD2 expression and decreased overall survival (p = 0.0023), relapse-free survival (p = 0.0013), and metastasis-free interval (p = 0.006) in patients with primary ER-negative breast carcinomas. In conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.
Introduction
In the course of recent breast cancer global gene expression studies we identified a distantly related rhomboid-like gene known as RHBDD2 (Rhomboid domain containing2) located at the 7qll.23 chromosomal region, to be markedly over-expressed in primary invasive carcinomas from patients that recurred within 6 years of follow-up [1] .
The human genome contains several rhomboid-like genes which can be phylogenetically grouped in three major classes [2] . The first class, includes the true active rhomboids genes that are subdivided into secretase (e.g. RHBDL-1/-2/-3 and RHBDD1 genes) and L' ARL-type subfamilies. The second class is composed of novel inactive rhomboids members, recently named as iRhoms group (e.g. RHBDF-1/-2 genes). The third group includes a small number of other distant evolutionary related and uncharacterized genes (e.g. RHBDD-2/-3f for which there is no evidence that they are active proteases. Rhomboid-like proteins function in diverse processes including quorum sensing in bacteria, mitochondrial membrane fusion/apoptosis (PARLf and stem cell diffe rentiation in eukaryotes [3, 4] . Also, rhomboid-like proteins have been recently linked to human diseases, including early-onset blindness, diabetes, and parasitic diseases [5] . However, the biological functions of the mammalian rhomboid-like family remains to be determined.
Here we present data supporting the role of RHBDD2 as a novel breast cancer-related gene. We demonstrate that RHBDD2 is over expressed at the mRNA and protein levels in breast cancer samples and in some of these cases due to gene amplification. Interestingly, analysis of publicly available breast cancer gene expression databases indicates that RHBDD2 is over-expressed in estrogen receptor-negative breast carcinomas from patients with poor prognosis. Finally, we show that in vitro RHBDD2 silencing regulates cell proliferation of breast cancer cells.
Material and methods

Serial analysis of gene expression database mining
To perform a comparative analysis of the human Rhomboid-like family members expressed in breast tissue Total protein extracts were prepared from a set of 7 breast normal and cancer cell lines (HME87, MCF10, MCF7, ZR75-30, T47D, BT47A, and BT549). As normal controls we also included human breast epithelial organoid protein extracts, obtained from three independent cosmetic mammoplastic specimens (B26, B27, and B28). Total cell protein lysates were made from frozen tissues using RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCI, 0.5% sodium deoxycholate, 1% Triton X-100, and 0.1% SDS) containing protease inhibitor cocktail (Roche, Mannheim, Germany). For Western blot, 50 pg of total protein was separated by 12.5% SDS-PAGE and transferred to PVDF mem branes (Millipore, Billerica, MA). Immunodetection was performed using Protein Detector™ (KPL, Gaithersburg, MD) Western blotting reagents as described by the manufacturer. RHBDD2 protein was de tected using an anti-RHBDD2 polyclonal primary antibodies and HRP conjugated anti-rabbit secondary antibody (KPL, 1:2000) followed by chemiluminescence autoradiography. Beta-actin protein (ACTB) was detected using monoclonal anti-actin antibody (ICN Biomedicals, Burlingame, CA, 1:1000) and HRP conjugated anti-mouse secondary antibody (KPL, 1:5000).
For immunofluorescence analysis, MCF7 and MCF10 smears from exponentially growing cells were prepared on glass slides and then fixed in cold acetone for 10 min. Anti-RHBDD2 polyclonal antibody was added to the slides at a 1:250 dilution, and incubated at room temperature during 1 h. Detection was performed using FITC-labeled secondary anti-rabbit IgG antibodies following standard immuno fluorescence methods.
RT-PCR and cDNA sequencing analyses
Total RNA was isolated from eleven frozen normal breast tissue derived from cosmetic mammoplastic specimens and three breast cancer cell lines (MCF7, T47D and ZR75) using TRI Reagent® (MCR Inc., USA). Quality control of RNA integrity was made by running out RNA samples onto formaldehyde denaturing 1 Samples were considered to be affected by genomic amplification for RHBDD2 when the ratio between net intensity bands was greater than + 3 SD (99% confidence interval, p<0.001) relative to the average value determined from 11 normal breast control samples. Experi ments were performed in triplicate for each data point.
¡n silico RHBDD2 gene expression and clinical data analysis
To further investigate correlations of transcriptional up-modulation of RHBDD2 gene and clinicopathologic parameters on larger breast carcinoma sets, data were obtained from a publicly available breast cancer microarray study [10] . Clinicopathologic and gene expression data from 295 primary invasive breast carcinomas (226 ER-positive and 69 ER-negative carcinomas) were collected from the Rosetta Inpharmatics website (http://www.rii.com/publications/ 2002/nejm.html). Two groups of patients were derived by using the median expression value of the Log2 ratio overall distribution for RHBDD2 probe (NM_020684) (RHBDD2 median = 0.017; high expres sion, greater than 0.017; and low expression, less than 0.017). KaplanMeier analysis was assessed with both groups using the Van 
RHBDD2 gene silencing and cell proliferation assay
Three siRNAs of 19-mer against RHBDD2 mRNA corresponding to coding sequences starting at positions 1326 (siRNA-Rl: 5'-CUGUGUUGGGUACUUUGAUdTdT-3'), 340 (siRNA-R2: 5'-GUCUACGAGAAUCCCAUCUdTdT-3') and 1050 (siRNA-R3: 5'-GCAGAACCACUUUGGUCCAdtdt-3') relative to the cDNA sequence AF226732 were synthesized (Bioneer Inc, Korea). The AccuTarget™ biotin-labeled negative control 5% SDS-PAGE and transferred to PVDF membranes. RHBDD2 protein was detected using a polyclonal anti-RHBDD2 antibody developed by our laboratory. The membrane was then probed with mouse monoclonal anti-actin antibody for normalization of differences in protein loading. Three normal human protein extracts prepared from breast organoids were included (B25, B26, and B27). The full-length R.HBDD2 protein (isoform 1) and the predicted splicing variant (isoform 2) are indicated. (B) Immunofluorescence and immunocytochemistry detection of RHBDD2 displayed a vesicular pattern compatible with an ER-like distribution in MCF7 cells (see Supplementary Fig. 1 ). MCF10 cell smears were used as the negative control demonstrating non cross-reactivity of the primary antibody. MCF7 cells without RHBDD2 polyclonal antibody was also used as negative control of the reaction (MCF7-NegCt). The nuclei were counterstained with propidium iodide (red fluorescence).
siRNA (siRNA-NegCt: 5z-CCUACGCCACCAAUUUCGUdTdT-3z) (Bioneer Inc, Korea) that exhibits no homology to any human genome sequence was used as a non-silencing reference. In addition, we included a positive control siRNA sequence (Termo Scientific Dharmacon, USA), [11] .
To enable visualization and illustration of the 7qll.2 chromosome region in some breast cancer cell lines from Pollack's array-CGH data [12] , we used the VAMP software (Visualization and Analysis of array-CGH, transcriptome and other Molecular Profiles) (http: //bioinfo-out. curie.fr/actudb). VAMP is a graphical user interface for visualization and analysis of genomic profiles [13] . The chromosome 7 array-CGH profiles previously generated by Pollack et al. [12] from MCF7, T47D and ZR75 breast cancer cell lines were download from the ACTuDB database at the same website [14] . 
Results
Human rhomboid family members expressed in breast epithelial cells
We analyzed the rhomboid-like family member gene expression profile in a set of normal and breast cancer SAGE libraries. Among the rhomboid family members, RHBDD2 and RHBDF1 were the most frequently expressed rhomboid-like genes in breast SAGE libraries (Fig. la) . Specifically, RHBDD2 was detected as being expressed in 100% of breast cancer cases (34 out of 34) according to SAGE database analyses, interestingly, among the rhomboid genes only RHBDD2 was identified as over-expressed in primary invasive breast carcinomas compared with normal breast samples (p<0.008) (Fig. lb) . No association was detected between the expression of this transcript and ERu status (p>0.05). (Fig. 2A) . RHBDD2 immunostaining displayed a granulate/vesicular pattern compatible with an endoplasmic reticulum-like distribution with accumulation in the perinuclear space of MCF7 and T47D cells (Fig. 2B and Supplementary Fig. 1 ). MCF10 cell smears were used as the negative control of the reaction demonstrating non cross-reactivity of the primary antibody (Fig. 2B) .
RHBDD2 expression analysis in normal and
We decided to investigate whether the different protein products were results of alternatively spliced RHBDD2 transcripts (isoform). RHBDD2 alternative splicing prediction based on ASAP (Alternative Splicing Annotation Project) bioinformatics analysis revealed two putative isoforms, here named as isoform 1 (full-length RHBDD2 mRNA) and isoform 2 (alternatively spliced isoform) (Fig. 3A) . To validate these findings, we first performed an RT-PCR analysis in MCF7, T47D and ZR75 breast cancer cell lines. Three pairs of PCR primers, based on EST sequences were used to amplify the RHBDD2 transcript from cDNA, and the products were sequenced. MCF7 and T47D cell lines showed high expression levels of RHBDD2 with any combination of PCR primers used for RT-PCR analysis (Fig. 3B, C) . Interestingly, primer pairs Fl/R located on the first and last exons of RHBDD2 mRNA respectively, result in two PCR products of approxi mately 1100 and 900 bp in MCF7 and T47D cell lines (Fig. 3A) . The luminal-tumor derived cell line ZR75 showed weak RHBDD2 mRNA expression. However, primer pairs F2/R and F3/R result in a unique RT-PCR product of 720 bp and 369 bp respectively as it was expected (Fig. 3B, C) and confirmed by direct DNA sequencing (data not shown). Bi-directional sequence analysis was performed on each purified RT-PCR product from the MCF7 cell line. Comparison of these sequences with the publicly available RHBDD2 genomic sequence (accession no. NT007933.14) confirmed gene identity for each PCR fragment and revealed that these two transcripts detected with the primer pairs Fl/R were generated by alternative RNA splicing of exons 1 and 2 of RHBDD2 (Fig. 3D) . These data suggest that the low protein product observed in the Western-blot analysis represents true RHBDD2 protein, demonstrating that the antibody used in our study detected the full-length RHBDD2 protein (isoform 1) as well as the alternative splicing variant (isoform 2) (Fig. 2) . In addition, this RT-PCR analysis showed undetectable or low expression of RHBDD2 gene in normal breast tissues analyzed (Fig. 3C ). These data corroborate the SAGE analysis showing that RHBDD2 mRNA/protein expression is highly elevated in some breast cancer cells compared with normal breast samples.
Increased RHBDD2 protein expression in breast cancer clinical specimens
To further investigate the relevance of RHBDD2 protein expres sion in breast cancer, we analyzed 213 breast tissue sections by immunohistochemistry (Table 1 and Fig. 4 ). We identified a statis tical significant increase in RHBDD2 protein expression from normal Fig-4 . RHBDD2 immunohistochemical staining in (A) normal breast adjacent tumor (xlOO), (B) hyperplastic breast lesion (xlOO), (C) ductal carcinoma in situ 1x400;, (D, E) ERctnegative invasive ductal carcinomas with RHBDD2 gene amplification (xlOO and x400 respectively), and (F) lymph node metastasis sample (x400). As negative control for immunohistochemical staining we used a tissue sample, without primary antibody incubation (G), derived from serial sections of a RHBDD2-positive invasive breast carcinoma (H). Fig. 4) . Non-statistical significant association was detected between RHBDD2 protein expression and ERa status as well as histologic tumor grade (p>0.05).
Overall, these data are in agreement with the SAGE profiling analysis, indicating that a high proportion of invasive breast carcino mas expressed significantly increased levels of RHBDD2 protein compared with normal breast samples. More importantly, strong RHBDD2 protein expression was highly associated with primary in vasive breast carcinomas with axillary lymph node metastases.
RHBDD2 gene is amplified in correlation with over-expression in breast cancer cells
Microarray-based comparative genomic hybridization evidence is available reporting the amplification of the chromosomal region 7qll.23 in breast cancer cell lines and primary breast carcinomas [12, 15] . To investigate the frequency of DNAgains/losses affecting the chromosome region 7qll.23, we performed a pooled re-analysis of 552 invasive breast carcinomas previously analyzed by array-CGH, available at Progenetix online database. Pooled estimates showed gain of chromosome region 7qll.23 in 11% of the analyzed cases (61 out of 552 IDC). The Visualization and Analysis of array-CGH, transcriptome and other Molecular Profiles (VAMP) [13] resource was employed for microarray-CGH data analysis of chromosome region 7qll.23 from MCF7, T47D and ZR75 breast cancer cell lines. In silico analysis of Pollack's data [14] identified a gain of chromosome regions 7qll.22-7qll.23 including the RHBDD2 gene region in MCF7 and T47D cell lines (Fig. 5A) . These data are in agreement with our Western-blot observations.
We used a competitive PCR method based on duplex PCR of RHBDD2 (target) and SLC13A1 (control) 
RHBDD2 SLC13A1
D (21 out of 98) primary invasive breast carcinomas analyzed (Fig. 5D) 
RHBDD2 gene silencing in vitro leads to reduced cell proliferation rate
To investigate whether RHBDD2 gene expression plays any role associated to cell proliferation; a knock-down assay was performed with specific siRNA sequences targeting RHBDD2 mRNA in MCF7 breast cancer cell line. Cells were treated with optimal concentrations of RHBDD2 siRNA and examined the number of viable cells 48 h after transfection.
RT-PCR and immunofluorescence analyses demonstrated an effective depletion of RHBDD2 at mRNA and protein levels in MCF7 by using the siRNA-Rl and siRNA-R3 sequences compared with the negative control siRNA (Fig. 6A and B) . MCF7 cells in the control group were treated with the siRNA-Ct, which had a randomized nucleotide sequence that had no significant homology to the human genome. siRNA-Rl and siRNA-R3 treated cells showed a significant decrease in proliferation 48 h after transfection compared to negative or positive control siRNAs (Fig. 6C) Next, we analyzed RHBDD2 expression with patient's outcome using the microarray data set of Van de Vijver et al [10] . Interestingly, we identified a significant association between high expression of RHBDD2 and short time relapse-free survival among 295 patients (p = 0.018; Fig. 7A ). Kaplan-Meier analysis revealed that RHBDD2 over-expression was particularly associated with shorter overall survival (p = 0.0023; Fig. 7B ), metastasis-free interval (p = 0.006; Fig. 7C ), and relapse-free survival (p = 0.013; Fig. 7D ) but surprisingly only in patients with ERa-negative breast carcinomas. Non-statistically significant associations were found for RHBDD2 expression and follow-up in patients with ERa-positive carcinomas (p>0.05).
Discussion
In a recent study using SAGE, we performed a comparative global gene expression profile of primary invasive breast carcinomas [1] .
• * " siRNA-Ct Tumor-specific up-regulation of some genes can be attributed to aberrant DNA amplification, a phenomenon frequently found in many breast tumors [12] . Usually genomic amplification in cancer involves genes that provide some sort of growth advantage or transformation to the cells bearing the amplification. Typically amplification involves growth factors, growth factor receptors, certain cyclins, transcription factors or co-activators, i.e. positive regulators of proliferation and by definition many are dubbed oncogenes. Interestingly, microarray based comparative genomic hybridization evidence is available reporting amplification of the chromosomal region 7qll.2 (the same region to which RHBDD2 maps) in breast cancer cell lines and primary breast carcinomas [12, 15] . Moreover, a genome-wide transcriptome map revealed clusters of genes located at 7qll.2 exhibiting non random increased expression in breast cancer cells [17] . To determine whether RHBDD2 [16] . More importantly, in a very recently study Zou et al. demon strated that RHBDF1 participates in the modulation of G proteincoupled receptor-mediated EGFR transactivation. Furthermore, RHBDF1 over-expression in head and neck cancer cells results in facilitated export ofTGFa [18] . These data suggest that RHBDF1 plays a critical role in the mechanism responsible for the production of activated EGFR ligand. Similar to the observations of Yan et al. [16] in our studies we found that siRNA-mediated silencing of RHBDD2 expression in MCF7 breast cancer cell line leads to a marked decrease in cell proliferation. Thus, the possibility exists that RHBDD2 may also play a role in signaling pathways related to cell proliferation/survival as shown for RHDBF1; as such it could be a protein of relevance in breast cancer initiation and progression. Interestingly, and supporting this speculation, in silico analyses revealed that patients whose tumors expressed high RHBDD2 had significantly shorter relapsefree survival when compared with those whose tumors had low RHBDD2 levels. More importantly, we found that high RHBDD2 expression was significantly associated with shorter overall survival, relapse-free survival, and metastasis-free interval in patients with ERa-negative breast carcinomas. These data are in line with our observation that increased RHBDD2 protein expression is associated with advanced tumor stages. In addition, we further confirmed our initial finding in which we observed a statistically significant over expression of RHBDD2 in primary tumors of patients who after follow up developed recurrent disease [1] , In summary, our findings indicate that RHBDD2 over-expression might play a role in breast cancer tumor progression facilitating the development of more aggressive pheno types in at least a subset of breast carcinomas. Further studies are required to elucidate the exact role of this protein in breast cancer.
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